Twenty to 25% of patients with chronic myelogenous leukemia (CML) treated with interferon-alpha (IFN-A) achieve a complete cytogenetic response (CCR). However, cells bearing rearrangement of BCR/ABL can still be detected many years after achieving a CCR despite the absence of clinical evidence of active disease. It has been suggested that the disease is kept in a dormant state by immune mechanisms. How this is achieved is not known, but it has been speculated that p210 BCR/ABL might be presented by malignant cells through HLA molecules, thus making them the target for specific immune cell killing. Because specific peptides will be expressed in association with certain HLA molecules, different HLA phenotypes could be associated with different response rates to IFN-A. The response to IFN-A-based therapies in 239 patients with chronic phase CML was analyzed according to their HLA phenotype. One hundred and ninety-four (81%) achieved complete hematologic response, 142 (59%) had a cytogenetic response which was
Introduction
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder of the pluripotent hematopoietic stem cell. The hallmark of the disease is the presence in 90 to 95% of patients of the Philadelphia chromosome (Ph) which represents a reciprocal translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11). 1 The translocation juxtaposes the proto-oncogene c-abl located on chromosome 9q34 to the BCR gene on chromosome 22q11, resulting in a chimeric gene, BCR-ABL. 1 Upon translation, a novel 210-kDa fusion protein is produced (p210 BCR/ABL ) with increased tyrosine kinase activity.
CML in early chronic phase and a cytogenetic remission in 35 to 55% of them. 2 Twenty to 25% of patients achieve a complete cytogenetic remission (ie 0% Ph-positive metaphases), and 10 to 15% a partial cytogenetic remission (ie 1% to 34% Ph-positive metaphases). Thus, a major cytogenetic response is achieved in 30 to 40% of patients. 2 Over 90% of complete cytogenetic responses are durable for periods ranging from 2 to 8 years. 3 Achieving a cytogenetic response with IFN-A is associated with an improved survival. 4, 5 A complete or partial cytogenetic remission is associated with a 5-year survival rate of approximately 90%. 4, 5 The mechanism of action of IFN-A is not clear but stimulation of a specific immune response has been suggested. [6] [7] [8] IFN-A has pleiotropic biologic effects, which include stimulation of cytotoxic activity of macrophages, natural killer lymphocytes and T lymphocytes, and upregulation of the surface expression of adhesion molecules and class I and class II HLA molecules. 9 It has been suggested that after treatment with IFN-A in CML, immune mechanisms keep the disease in a 'dormant' state. 6 Indirect evidence suggests that immune mechanisms may play a role in the response to IFN-A. For example, approximately 5% of CML patients treated with IFN-A develop autoimmune complications ranging from hypothyroidism to connective tissue diseases. 10 The cytogenetic response rate among these patients is 70%. 10 A specific anti-CML immune response would target antigens present only in neoplastic cells. p210 BCR/ABL could represent such an antigen since it is only present in leukemic cells and the junction of two normal proteins may create an antigenic site. 8 The fusion at the RNA level comes inside a codon, translating into a new amino acid, not corresponding to the normal sequence of either BCR or ABL. 11 Several studies have documented the immunogenicity of peptides derived from p210 BCR/ABL . 12, 13 However, p210 BCR/ABL is an intracellular protein and to stimulate a specific immune response it would have to be expressed in the cell surface. Antigens are presented to immune cells via HLA molecules, and it has been suggested that peptides derived from p210 BCR/ABL may be presented by specific HLA molecules and trigger a specific immune response to CML cells. 8 The expression by HLA molecules is sequence-specific, 14, 15 and binding of p210 BCR/ABL -related peptides has been documented to some HLA molecules. 16 Therefore, it could be speculated that expression and potentially response to IFN-A could correlate with the HLA phenotype.
To address this issue we investigated the response to IFN-A in patients with chronic phase CML who had an HLA phenotype analyzed at our institution to identify whether the HLA phenotypes correlate with the response to IFN-A.
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Materials and methods
Study group
All patients with a diagnosis of Ph-positive, chronic phase CML who received IFN-A as their primary treatment at MD Anderson after referral to our institution from 1982 to 1994 and whose HLA phenotype was investigated were included in this analysis. Patients were treated in one of several sequential studies including human leukocyte IFN-A, recombinant human IFN-A alone, recombinant IFN-A and interferon-␥, recombinant IFN-A and hydroxyurea, and recombinant IFN-A and low-dose Ara-C. The results of treatment with IFN-A for the majority of these patients have been previously reported. 4 Bone marrow aspirates with morphologic and cytogenetic analysis were performed before treatment, every 3 months during the first 2 years of follow-up, and every 4 to 6 months thereafter. Informed consent was obtained prior to therapy with the IFN-A protocols according to institutional guidelines. Therapy IFN-A was given at a daily dose of 5 × 10 6 U/m 2 subcutaneously as previously reported. 4 The IFN-A was reduced by 25% for persistent grade 2 toxicity. For grade 3 or 4 toxicity, IFN-A was interrupted until resolution of the toxicity, and therapy was then restarted at 50% of the dose. Toxicity grading was according to the National Cancer Institute guidelines. 17 The dose was also reduced by 25% if the leukocyte count was lower than 2 × 10 9 /l or if the platelet count was lower than 60 × 10 9 /l.
Response criteria
Response criteria were defined as previously described. 18 A complete hematological response was defined as normalization of the peripheral blood counts and differential, including a leukocyte count less than 10 × 10 9 /l, a platelet count of less than 450 × 10 9 /l, with an absence of immature blasts, promyelocytes or myelocytes, and disappearance of all signs and symptoms of the disease. Patients achieving a CHR were further categorized by their best cytogenetic response (lowest percentage of Ph-positive metaphases): (1) complete cytogenetic response, if the lowest percentage of Ph-positive was 0%; (2) partial cytogenetic response, if it was between 1% and 34% and (3) minor cytogenetic response, if it was between 35 and 90%. A major cytogenetic response included complete and partial cytogenetic responses, that is, patients with the lowest Ph-positive metaphase percentage below 35%.
HLA typing
The study of HLA phenotype was carried out as part of the initial work-up of the patients anticipating the possibility of a bone marrow transplantation. HLA typing was performed at our institution with standard serological techniques by using HLA antigen-specific allo-antisera or monoclonal antibodies.
PCR amplification of the chimeric BCR/ABL transcript
Detection of the chimeric BCR/ABL mRNA by PCR was performed as previously described. 19 Briefly, an antisense oligonucleotide derived from the sequence of exon 2 of c-abl was used to synthesize the first strand cDNA from the RNA samples. An oligonucleotide derived from exon 2 of the bcr region was then added along with Taq polymerase (PerkinElmer Cetus, Norwalk, CT, USA) and PCR buffer. PCR was performed in a Thermocycler (Perkin-Elmer Cetus) for 35 cycles as previously described. 19 Ten microliters of PCR amplified products were loaded onto a 3% NuSieve agarose gel and size fractionated at 60 V for 5 h and transferred to a nylon membrane after denaturation. The membrane was hybridized with a mixture of 5′-end radiolabeled probes L-6 and K-28, which were derived from the sequences at the BCR/ABL junctions of b2a2 and b3a2 mRNAs, respectively. The membrane was then washed and autoradiographed. Special precautions were undertaken to prevent contamination while performing PCR as previously described, 20 and PCR was performed in duplicate to ensure consistency of the results.
Prognostic models
In order to compare the different subgroups, we used a prognostic model previously proposed by our group. 21 Patients are categorized as having stage 1, 2, or 3 disease (good-, intermediate-, and high-risk, respectively) if they have none or one (stage 1), two (stage 2), or three or more (stage 3) of the following poor prognostic features: (1) age equal or greater than 60 years; (2) peripheral blasts у3%, or bone marrow blasts у5%; (3) peripheral basophilia у7%, or marrow basophils у3%; (4) platelet counts у700 × 10 9 /l; and (5) splenomegaly у10 cm below the costal margin. A significant association between risk group and response to IFN-A and survival has been previously reported. 4 
Statistical methods
The outcomes evaluated in this study were the frequency of cytogenetic response and the survival duration. These two parameters of response were correlated with the HLA phenotype. Survival was measured from the time of diagnosis. The comparison of clinical characteristics and cytogenetic reponses among different HLA groups was done using 2 with Yates correction or Fisher exact test as indicated. Survival analysis was based on Kaplan-Meier estimation 22 and comparisons analyzed by the log-rank test. 23 
Results
The clinical characteristics of the 239 patients analyzed are shown in Table 1 . Their median age was 40 years (range, 14 to 72 years). The median time from diagnosis to start of IFN-A therapy was 2 months (range, 0-186 months), with 12 patients (5%) treated later than 12 months after the diagnosis (ie in late chronic phase). According to the prognostic model, 151 patients (63%) were in stage 1, 46 (19%) in stage 2, and 24 (10%) in stage 3. In 18 patients (8%) not enough information was available for staging with this model. These characteristics are similar to the characteristics of the overall population recently reported 4 and the population is therefore representative of all patients treated with IFN-A.
A complete hematologic response was achieved in 194 patients (81%). One hundred and forty-two patients (59%) achieved a cytogenetic response that was complete in 71 4 and this population can therefore be considered representative of the overall population of patients treated with IFN-A at our institution.
The frequency of HLA class I molecules expressed in the 239 patients studied is presented in Table 2 . The most fre- quently expressed HLA-A antigens were A2 in 110 patients (46%), A1 in 75 (31%), A24 in 49 (21%), and A3 in 38 (16%).
The most common HLA-B antigens were B44 in 55 patients (23%), B35 in 51 (21%), B7 in 46 (19%), and B8 in 40 (17%). This population consists of 87% white Americans, 6% African-Americans, 6% Hispanics, and 1% other races. Therefore, the frequency of HLA phenotypes is representative of the normal distribution of HLA class I antigens in the general population, considering the predominance of white Americans. 24 For the comparative analysis, we considered all HLA groups which included at least 10 patients. The median age, time to treatment with IFN-A, pretreatment hemoglobin, platelet, and white blood cell counts, percentage of blasts and basophils in peripheral blood and bone marrow, frequency of asymptomatic patients at diagnosis, and percentage of patients in late chronic phases were similar in all HLA groups (data not shown). The similarly is best represented by the distribution by stage according to the synthesis model which is comparable among all groups (Figure 1) .
The rate of cytogenetic responses and major cytogenetic responses by HLA group is shown in Table 3 . The group with the best response rate was that of patients with HLA-B27: 11 patients (79%) achieved a cytogenetic response, including eight patients (57%) with a complete, and two (14%) with a partial cytogenetic response, for a total of 10 patients (71%) achieving a major cytogenetic response. This compares favorably to 39% of major cytogenetic responses and 29% of complete cytogenetic responses for the whole cohort, and is significantly better than the response in patients without HLA-B27 (P = 0.02 for MCR). A favorable trend in the rate of major cytogenetic responses was also noticed in other HLA groups, including HLA-B35 (25/51, 49%; P = 0.13), HLA-A3 (19/38, 50%; P = 0.14), and HLA-A31 (9/15, 60%; P = 0.10). A negative trend was identified for patients with HLA-B18 with only three of 18 patients achieving a major cytogenetic response (17%, P = 0.04).
There was a trend for improved survival for patients with HLA-B27 where the median survival has not been reached and 77% of patients are alive at 5 years. These figures are not statistically different from those for patients without HLA-B27 (P = 0.5) probably because of the small number of patients in (Table 4) . A favorable trend was also observed for patients with HLA-A31, whose median survival has not been reached, and 86% were alive at 5 years (P = 0.16). A shorter survival was identified for patients with an HLA-A2 phenotype who had a median survival of 61 months (P = 0.04). Patients with a HLA-B7 phenotype also had a shorter median survival (56 months; P = 0.007). An unfavorable trend was also observed in patients with HLA-B18 who had a median survival of 63 months (P = 0.15). Peptides derived from the junction sequence of p210 BCR/ABL have been suggested to bind specifically to certain HLA molecules. 8, 16 We therefore analyzed whether expression of b3a2 or b2a2 correlated with response to IFN-A by HLA phenotype. Data on the BCR/ABL junction was available in 105 patients (44%): 53 (50%) had b3a2, 44 (42%) had b2a2, and there was evidence of both sequences in eight patients (8%). The rate of major cytogenetic response was similar for patients with b3a2 (22 patients, 42%), and b2a2 (21 patients, 48%), and was comparable to that of patients where this information was not available (49 MCR in 134 patients, 37%). Only one of the eight patients with both signals had a MCR (13%), but the difference is not significant (P = 0.23) probably due to the small number of patients. The response by HLA phenotype and breakpoint is shown in Table 5 . None of the HLA groups had a significant association between MCR to IFN-A and the type of mRNA message (b3a2 or b2a2).
Discussion
The results from this analysis suggest that there might be an association between HLA phenotype and response to IFN-A therapy in patients with CML. Patients with certain HLA phenotypes such as HLA-B27 and A-31 may have a better response to therapy than the average, whereas others such as HLA-B18 may have a worse response. Accordingly, certain HLA phenotypes are associated with an improved survival, whereas others have a poor outcome. The observation of some association between expression of certain HLA molecules and response to IFN-A is interesting in view of some of the current evidence of immune mechanisms in CML.
The role of immune mechanisms in the eradication of CML is not clear but several pieces of evidence support the impression that they play a significant role. 8 Probably the most compelling evidence is the graft-versus-leukemia effect which is best documented after allogeneic bone marrow transplantation in patients with chronic phase CML. 25 Although the mechanism of action of IFN-A in CML is not completely understood, it has been suggested that immune modulation may play a role. [6] [7] [8] In some patients BCR/ABL eventually becomes undetectable by PCR after treatment with IFN-A, but residual disease can still be detected in progenitor cells. 6 This suggests that the disease persists in a dormant state with no clinical or cytogenetic evidence of disease, and it has been suggested that immune mechanisms can control the disease at this stage. 6 The protein product of the Philadelphia chromosome p210 BCR/ABL has been proposed as a candidate for mediating a specific immune response since it is only present in leukemic cells. 8 The fusion of ABL with BCR at the RNA level comes inside a codon and translates into a new amino acid which does not correspond to the normal sequence of either BCR or ABL, thus forming a sequence with immunogenic potential. 11 Several studies have documented the immunogenicity of peptides derived from p210 BCR/ABL which are capable of triggering both humoral 12 and cellular 13 immune reactions. This protein however is intracytoplasmic, and to trigger an immune response in vivo it would have to be presented in the surface of malignant cells. Both class I and class II HLA molecules bind immunogenic peptides and present them to T cells for specific immune recognition, with exogenous antigens presented by class II molecules and endogenous peptides via class I molecules. 15, 26 It has been proposed that T cells could recognize endogenously processed products of the p210 BCR/ABL expressed in the cell surface by binding to MHC molecules. The fused peptide may represent the junction or other sequences that could bind specific MHC motifs. 8 Binding of p210 BCR/ABL junction peptides to class I MHC has been documented in vitro using cell lines deficient in transporter associated with antigen presentation proteins. 27 These cells express very low levels of class I molecules on their surface because the class I molecules that reach the cell surface lack a bound peptide and are unstable. When cultivated in the presence of a peptide with high affinity for class I molecules they are stabilized and expression increases. The presence of peptides derived from the b2a2 junction segment of p210 BCR/ABL increased expression of class I molecules in a murine cell line suggsting that these peptides can bind with high affinity to some class I molecules. More direct evidence was provided by Bochia et al 16 who investigated 76 peptides, 8 to 11 amino acids long, spanning the b3a2 and b2a2 junctional regions of the p210 BCR/ABL for binding to HLA molecules. Twenty-one peptides were predicted to have the potential to bind class I molecules based on their sequence. Four of these peptides bound to purified A3, A11, or B8 HLA molecules with high or intermediate affinity. All four binding peptides correspond to the b3a2 junction sequence, whereas none of the peptide from the b2a2 sequence bound any of the HLA molecules tested. 16 When mononuclear cells from healthy donors were stimulated with autologous antigenpresenting cells, pulsed with HLA-binding peptides (with the b3a2 junction sequence) and mixed in a cytotoxicity assay with an HLA-matched leukemia cell line previously pulsed with the same peptide, cytotoxicity was documented in all four HLA-A3 donors tested. The cytotoxic reaction was specific to the HLA-binding peptide. 28 However, all experiments included cell lines pulsed with the peptides, and there has been no documentation yet of these peptides being naturally processed and presented in the cell surface of CML cells. Richiardi et al 29 investigated the frequency of HLA-A and -B alleles comparing CML patients with b3a2 and b2a2 fusions of BCR/ABL. They did not identify a difference in the distribution of HLA-A or -B phenotypes between the two groups. In this series we also did not find an association between the response. 31 These PR-1-specific lymphocytes can lyse fresh CML blasts and inhibit CML colony-forming units in vitro, 31, 32 although no direct evidence of proteinase 3-related peptides naturally bound to HLA molecules exists. Finally, some HLA class I molecules share similar peptide-binding motifs and have been grouped into HLA supertypes. 33 One such family, the HLA-A3-like supertype, comprises products from the HLA class I alleles A3, A11, A31, A*3301, A*6801. 34 Interestingly, the b3a2 junctional peptides found to bind HLA class I molecules by Bocchia et al, 16 bind to at least two members of this superfamily. In our analysis, patients with HLA-A3 or A-31 had some of the better major cytogenetic response rates, but further analysis of the significance of this will require a more precise definition of these and other supermotifs, and a larger population sample.
The possibility that the association described here is a statistical artifact of multiple comparisons should be considered. When a high number of independent comparisons is made, the probability of finding at least one false-positive result increases significantly. 35 If judged by the Bonferroni criterion 36 to determine whether the significance is impaired by the multiple comparisons, most of the associations lose their statistical significance. However, the multiple comparisons are not completely independent from each other and the true statistical significance of these observations is difficult to estimate. This analysis also underestimates the presence of companion alleles, but an analysis of extended haplotypes would require a much larger population. Therefore, it is possible that the statistical significance shown in our results is overestimated. However, rather than considering the numeric value of the association, it is important to consider the possible biologic implications of this observation and dissect it further.
We conclude that an association between certain HLAphenotypes and responses to IFN-A therapy in patients with CML may exist. The clinical significance and biologic mechanism of this possible association require a further investigation.
